
Alzheimer's risk could rise with specific sleep pattern, experts warn
The research from China, published in the journal Alzheimer's & Dementia by the Alzheimer's Association, analyzed the sleep cycles of 128 adults in varying states of cognition.
The study found that the highest occurrence of REM latency — which is when it takes longer for someone to reach the first REM period after drifting off to sleep — was associated with the highest risk of Alzheimer's.
The researchers concluded that prolonged REM latency may serve as a "novel marker of risk factor" for Alzheimer's disease and related dementias.
Dr. Wendy Troxel, senior behavioral scientist at the RAND Corporation in California, said this study adds to "growing evidence" that specific sleep features, like prolonged REM sleep, are linked to Alzheimer's biomarkers.
"REM sleep is the stage of sleep when dreams mostly occur, and is critically important for memory consolidation and emotional processing," Utah-based Troxel, who is also author of "Sharing the Covers: Every Couple's Guide to Better Sleep," told Fox News Digital.
This new research aligns with findings from Troxel's own lab, which have shown that other signs of poor sleep health — like shorter duration and poor quality — are associated with worse cognitive function.
"Sleep disruptions may contribute to the buildup of amyloid and tau proteins, key features of Alzheimer's pathology," the sleep expert said.
"But it's also important to note that the Alzheimer's disease process itself can disrupt sleep, suggesting a bidirectional association between sleep problems and cognitive decline."
Dr. Giulio Taglialatela, vice president and research institute director of the Brain Health Institute at the University of Texas Medical Branch, reacted to these findings in a separate interview with Fox News Digital.
Taglialatela said it's been "long understood" that getting a good night's sleep is associated with a lower risk of developing dementia.
"Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle," he noted.
"Unfortunately, there is nothing an individual can do to control how long it takes to enter REM sleep," the expert."
"Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's."
However, the expert said, the findings provide a "promising avenue" for predicting the likelihood of someone eventually developing dementia.
"Early intervention in Alzheimer's is essential for delaying its progression, and measuring REM sleep could be a marker to indicate who may be a candidate for treatment even before they start to show impaired cognitive function," Taglialatela said.
The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, "and thus the direction of the association cannot be determined."
The sample size was also relatively small, and the researchers only focused on one specific type of tau protein.
There is also the possibility that monitoring sleep in a clinical setting may introduce "environmental disturbances," impacting sleep measurement accuracy, the researchers noted. "Future studies will benefit from research in real-world home settings," they wrote.
While these findings are important, Troxel said, she encourages individuals to not allow the information to be "another source of worry that keeps you awake at night."
"Avoid the tendency to become overly fixated on metrics like REM sleep percentage or latency from consumer sleep trackers, as they have limited accuracy in determining sleep architecture," she cautioned. "Obsessing on such data can increase anxiety, which is a powerful sleep disruptor."
The best approach is to focus on the foundations of good sleep health, the expert said.
Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to Troxel.
"Obsessing on such data can increase anxiety, which is a powerful sleep disruptor."
"Minimize common disruptors such as excessive caffeine and alcohol, which are known to fragment REM sleep, [as well as] screen use before bedtime," she added.
"Focusing on these core sleep habits is the most effective and evidence-based way to support the brain and overall health."
Taglialatela also encourages individuals to focus on creating an "ideal sleep environment" while maintaining "good bedtime habits" to reduce the risk of developing Alzheimer's.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
an hour ago
- Forbes
Is The Mental Health System Broken Or Was It Never Built To Work?
Five years ago, a research team at Stanford achieved what many in psychiatry had long hoped for: A treatment for severe depression that worked rapidly, reliably, and without medication. In their 2020 SAINT trial, 19 out of 21 participants with treatment-resistant depression achieved remission after just five days of transcranial magnetic stimulation (TMS). It was a landmark moment. Yet today, the treatment remains almost entirely inaccessible to the average patient. Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is still paid for out of pocket, costing roughly $20,000, and insurers have been slow to move. A paradox at the heart of American mental healthcare: as innovation accelerates, access stalls. Over the last five years, more than $13 billion has been invested in the sector, but outcomes haven't improved in kind. Patients still cycle through multiple failed treatments. Clinicians are burnt out, and payers are stuck making decisions with no data. It's tempting to say the system is broken. But perhaps it was never built to do what we're now asking of it. A System Built for Simplicity, Not Reality Modern mental healthcare still relies on a medical model designed for acute illness: assess symptoms, assign a diagnosis, and prescribe a standard treatment. It's a linear approach that works well for infections and injuries. But mental illness is not linear. A messy intersection of biology, trauma, environment, and social context shapes conditions like depression, PTSD, and OCD. There's no single cause, no universal treatment. And yet, the system continues to reduce people to diagnosis codes and protocol templates, often leaving naivety at the door. This reductionist model doesn't reflect the complexity of the human experience, and it leaves patients, clinicians, and payers with more questions than answers. The system doesn't work for anyone. Yet, the misalignment of incentives means that all stakeholders are working against one another. Payers prioritize risk management—and in the absence of meaningful data, default to spending as little as possible. Providers focus on individual outcomes. Pharma chases scalable efficacy. Patients just want relief. But it seems no one is working with the correct information, and the frustration and disappointment are palpable. Data alone doesn't matter, because it's about how you use the data to drive change, according to Brayden Efseroff, psychiatrist and Chief Medical Officer at Allia Health. 'When patients cycle through multiple failed treatments before finding relief, it's not just frustrating - it's a sign of systemic dysfunction. Decisions are being made without context.' Ariel Ganz, PhD, a precision mental health researcher at Stanford, agrees, 'The same data clinicians need to design effective treatment plans is also critical for payers to manage risk, researchers to improve understanding, and patients to advocate for themselves on their health journey. 'Without more high-quality data, none of these parties can effectively improve patient outcomes.' Precision Mental Health Company is addressing this issue at its core. Their AI-native electronic health record (EHR) isn't designed to replace therapists or psychiatrists, but to support them by capturing, organizing, and translating real-world data into usable, structured insights. This innovative solution holds the promise of a brighter future for mental healthcare. Instead of extracting revenue from clinicians through software subscriptions or taking a percentage of their reimbursement, payers partner directly with Allia on value-based contracts. They're paid only when patients achieve measurable improvements, a stark contrast to the fee-for-service model that rewards volume over outcomes. Amie Leighton, CEO of Allia Health, discovered the need for better data firsthand during years of cycling through hospitals and treatment before finally receiving adequate care. The turning point came when her clinicians had access to complete information about her and were able to communicate with each other - something that had been missing throughout her previous treatments. This personal experience, and the empathy it engenders, shaped the company's mission: to build the infrastructure that allows for context-rich, coordinated, and personalised care. The Bigger Picture How do you fix a system that was never designed to work in the first place? We still have a long way to go, but for the millions of Americans struggling with mental health challenges, finally, an infrastructure-first approach offers something that's been missing: a system designed to actually help people recover. In an industry where patients commonly endure multiple failed treatments before finding relief, this represents a significant shift toward care that prioritizes outcomes.
Yahoo
2 hours ago
- Yahoo
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. In June 2025, Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) presented the first-in-human Phase I/IIa clinical trial data (NCT05785741) of DB-1310 in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumors who had failed standard therapies. Dr. Hua Mu, Global Chief Medical Officer of DualityBio, stated: "DB-1310 demonstrated encouraging clinical efficacy and manageable safety in patients with EGFRm nsqNSCLC and multiple solid tumors. It is noteworthy that preclinical investigations of DB-1310 in combination with EGFR TKIs and other anticancer agents have also demonstrated robust synergistic tumor suppression activity. We will spare no effort to accelerate the clinical development of DB-1310 and look forward to its potential, as a next-generation HER3 ADC, to become a novel therapeutic option for a broad population of cancer patients." About DualityBio Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2,000 patients for multiple clinical-stage ADC candidates. Additionally, DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. For more information, please visit View original content to download multimedia: SOURCE Duality Biotherapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Elon Musk's Company Achieves Major Breakthrough
Elon Musk's Neuralink is continuing to make advancements, with the company achieving a first over the weekend. According to Neuralink, it has successfully implanted its brain-computer interface (BCI) in its eighth and ninth participants. In addition, Neuralink revealed that both implants were done on the same day, which had never been done before. "We successfully completed both P8 and P9 this weekend, our first time performing two surgeries in one day," Neuralink wrote. "Both participants are recovering well and in great spirits. We are looking forward to supporting them on their Neuralink journey." Neuralink has already helped paraplegics in clinical trials, with the BCI chip enabling them to control a computer and robot arms with their thoughts. The hope is that one day the device will help those same people walk again. But Musk also believes the implant will help those who are deaf or hard of hearing and others with dementia down the road. "Neuralink will do life-changing good for ultimately millions, maybe billions, of people," Musk predicted. "Imagine your loved one being able to walk again or your parent with dementia being able to recognize their child again." Completing two surgeries in one day is a big step for Neuralink, as now it'll be possible for the company to help more people in a shorter amount of time. Whether or not Neuralink's device will be able to do what Musk says remains to be seen, but it's moving in the right Musk's Company Achieves Major Breakthrough first appeared on Men's Journal on Jul 21, 2025